Open AccessGemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
Author(s) -
Yangyang Ma,
Yin Liu,
Yanli Xing,
Hongmei Li,
Jibing Chen,
Lizhi Niu
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i22.5564
Subject(s) - medicine , irreversible electroporation , gemcitabine , oncology , pancreatic cancer , cancer , gastroenterology , electroporation , biochemistry , chemistry , gene
Locally advanced pancreatic cancer (LAPC) is a common malignant digestive system tumor that ranks as the fourth leading cause of cancer-related death in the world. The prognosis of LAPC is poor even after standard treatment. Irreversible electroporation (IRE) is a novel ablative strategy for LAPC. Several studies have confirmed the safety of IRE. To date, no prospective studies have been performed to investigate the therapeutic efficacy of conventional gemcitabine (GEM) plus concurrent IRE.